HOME >> BIOLOGY >> NEWS
Experimental smallpox vaccine protects against monkeypox in nonhuman primates

Scientists evaluating MVA, a potential safer replacement for the licensed Dryvax smallpox vaccine, have shown that MVA elicits an immune response comparable to that of Dryvax in a monkeypox model of human disease. In addition, MVA protected nonhuman primates exposed to lethal doses of the monkeypox virus.

The study, published in the March 11th issue of the journal NATURE, is a collaborative effort involving a team of scientists from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the National Institute of Allergy and Infectious Diseases (NIAID), the Henry M. Jackson Foundation, and the University of Pennsylvania.

Their findings represent an important step in the search for an alternative vaccine to Dryvax, which contains a live virus called Vaccinia that carries a high risk of adverse complications for people with suppressed immune systems.

Smallpox, a devastating disease caused by the Variola virus, was eradicated in 1979 through the efforts of the World Health Organization (WHO). Currently, infectious Variola (a species of the genus Orthopoxvirus) is known to exist only in two WHO-sanctioned repositories, one in Russia and the other at the Centers for Disease Control and Prevention in Atlanta. However, there is concern that undisclosed reference stocks of the virus may exist, and its potential as a biological weapon has led to the production and stockpiling of smallpox vaccine and the immunization of some healthcare workers.

Because Variola no longer occurs naturally, vaccines cannot be tested for their ability to prevent smallpox in humans. Thus, licensing of future vaccine candidates will include studies of immune response and protection in nonhuman primates. According to the authors, monkeypox currently provides the best nonhuman primate model of an Orthopoxvirus infection.

MVA is made from the same Vaccinia virus present in the Dryvax product. The difference is that MVA is extremely at
'"/>

Contact: Caree Vander Linden
Caree.Vander-Linden@amedd.army.mil
301-619-2285
US Army Medical Research Institute of Infectious Diseases
10-Mar-2004


Page: 1 2

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental Biology 2004 - Translating the Genome
4. Experimental Biology 2004 meets in Washington, D.C. April 17-21
5. Experimental hantavirus vaccine elicits strong antibody response in primates
6. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
7. Experimental Biology 2003 meets in San Diego April 11-15
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental gene switch increases lifespan with no ill effects
10. Experimental therapy stops allergic reactions in mice
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2018)... (PRWEB) , ... August 16, 2018 , ... With increasing ... execution of basic research projects, are presenting multiple challenges. To be successful in such ... to execute the different aspects of the multiple tasks needed to develop a new ...
(Date:8/17/2018)... ... 16, 2018 , ... Cryo-Cell International, Inc. (OTC:QB Markets Group ... and store stem cells in 1992, announced that Arthur Ellis, JD, Board President ... and Managing Partner IsZo Capital, have joined the Company’s Board of Directors. , ...
(Date:8/15/2018)... ... ... The Florida Chiropractic Association’s National Meeting on August 16th-19th in Orlando, ... U.S. will gain firsthand insights into the new laser’s advancements and superior treatment abilities. ... trial that has resulted in the granting of an FDA 510(k) market clearance for ...
Breaking Biology News(10 mins):
(Date:8/26/2018)... ... August 24, 2018 , ... ExoCoBio ... exosomes dramatically relieves atopic dermatitis and inhibits a variety of inflammatory targets in ... paper, the symptoms of mice having severe atopic dermatitis were significantly improved after ...
(Date:8/23/2018)... ... , ... Visikol began its journey in late 2012 as an ... mentors, the Rutgers Technology Transfer team and Foundation Venture Capital Group, Visikol Inc was ... successful biotech company has been a circuitous path but was due in large part ...
(Date:8/21/2018)... Conn. (PRWEB) , ... August 21, 2018 , ... The ... 40, an annual recognition of the fastest growing technology companies in Connecticut. This year’s ... be held on Wednesday, October 3, at the Connecticut Convention Center in Hartford. A ...
(Date:8/17/2018)... ... August 16, 2018 , ... KCAS Bioanalytical and Biomarker ... expansion of their team. Dr. Dawn Dufield, Ph.D., joins KCAS as Director of ... LC-MS/MS group that will specialize in developing quantitative LC-MS/MS assays for biopharma molecules. ...
Breaking Biology Technology:
Cached News: